CytoDyn Inc.

CYDY ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2023 FY2022 FY2021
Revenue $0 $266.0K $0
Cost of Revenue — $53.0K —
Gross Profit — $213.0K —
Gross Margin — 80.1% —
Operating Expenses
Research & Development $2.6M $27.0M $53.4M
SG&A Expense $17.1M $44.3M $34.3M
Operating Income $-40.6M $-145.4M $-104.6M
Operating Margin — -54,663.2% —
Interest Expense — — —
Pretax Income $-79.8M $-210.8M $-176.5M
Income Tax Expense $0 $0 $0
Net Income $-79.8M $-210.8M $-176.5M
Net Margin — -79,255.6% —
EPS (Basic) $-0.10 $-0.31 $-0.30
EPS (Diluted) $-0.10 $-0.31 $-0.30
Shares Outstanding (Basic) 836.5M 676.9M 587.6M
Shares Outstanding (Diluted) 836.5M 676.9M 587.6M
Dividends Per Share — — —